Finerenone is in clinical development for the treatment of chronic kidney disease in adults with type 2 diabetes mellitus. Diabetes is a condition that causes the blood sugar level to become too high. The majority of diabetes cases are type 2 diabetes, where the pancreas does not produce enough insulin or when the cells in the body do not respond properly to insulin. Diabetes is the leading cause of chronic kidney disease and failure in adults. People affected by chronic kidney disease have a reduced life expectancy and lower quality of life, as well as substantially increased risk of heart disease and adverse health outcomes.
Finerenone is selective inhibitor of a specific protein, which blocks the damaging effects of hormones (such as aldosterone and cortisol) which can cause damage to the heart and kidneys in diabetic patients. Finerenone is administered orally in tablet form, and evidence suggests it may offer organ protection compared to similar inhibitors which are currently used. If licensed, finerenone will offer patients with type 2 diabetes mellitus who have chronic kidney disease an add-on therapy to slow down long-term kidney damage and reduce the adverse impact on the structure and function of the heart and vessels.
Ozanimod, administered orally, is a new sphingosine 1-phosphate (S1P) receptor modulator. Treatment with S1P modulators is believed to work by interfering with signalling pathways that contribute to tissue inflammation. If licensed, ozanimod will offer an additional treatment option for adult patients with moderate to severe UC who have had an inadequate response, lost response to, or were intolerant to conventional therapy or a tumour necrosis factor-alpha (TNF) antagonist. In one phase II clinical trial, ozanimod at a daily dose of 1mg resulted in a slightly higher rate of clinical remission of ulcerative colitis than placebo.